- Study: Participation in diabetes education associated with greater ability to self-manage
- Research Now launches diabetes panel
- Study pinpoints protective genetic mutations for Type 2 diabetes
- Report: Sugar accounts for 17% of normal U.S. diet as Type 2 diabetes accounts for $500 billion in global healthcare spending
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
BETHESDA, Md. Relatively healthy patients with Type 2 diabetes experienced a significant reduction in blood-sugar levels when taking an investigational treatment for Type 2 diabetes made by Spherix, the biotechnology company said Thursday.
Spherix announced results of a phase-3 trial of D-tagatose, which showed that the drug was more effective in American patients than in Indian patients.
“These are promising results, and we are pleased with the significant drop in HbA1c levels among patients treated with D-tagatose,” Spherix CEO Claire Kruger said. “As a monotherapy in a patient population with mild disease, this achievement is even more compelling.”